The Potential Applications of Artificially Modified Exosomes Derived from Mesenchymal Stem Cells in Tumor Therapy

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Jan 22

PMID 38250549

Authors

Yilin Song

Quanlin Song

Daosheng Hu

Binwen Sun

Mingwei Gao

Xiangnan Liang

Boxin Qu

Lida Suo

Zeli Yin

Liming Wang

Affiliations

Soon will be listed here.

Abstract

Mesenchymal stem cells (MSCs) have tumor-homing ability and play critical roles in tumor treatment, but their dual influences on tumor progression limit their therapeutic applications. Exosomes derived from MSCs (MSC-exosomes) exhibit great potential in targeted tumor treatment due to their advantages of high stability, low immunogenicity, good biocompatibility, long circulation time and homing characteristics. Furthermore, the artificial modification of MSC-exosomes could amplify their advantages and their inhibitory effect on tumors and could overcome the limit of tumor-promoting effect. In this review, we summarize the latest therapeutic strategies involving artificially modified MSC-exosomes in tumor treatment, including employing these exosomes as nanomaterials to carry noncoding RNAs or their inhibitors and anticancer drugs, and genetic engineering modification of MSC-exosomes. We also discuss the feasibility of utilizing artificially modified MSC-exosomes as an emerging cell-free method for tumor treatment and related challenges.

Citing Articles

Exploring the roles and clinical potential of exosome-derived non-coding RNAs in glioma.

Jin P, Bai X IBRO Neurosci Rep. 2025; 18:323-337.

PMID: 40034544 PMC: 11872630. DOI: 10.1016/j.ibneur.2025.01.015.

Mesenchymal stromal cell exosomes for drug delivery of prostate cancer treatments: a review.

Wang C, Feng Y, Rong X, Yan J, Lv B, Jiang H Stem Cell Res Ther. 2025; 16(1):18.

PMID: 39849570 PMC: 11755940. DOI: 10.1186/s13287-025-04133-8.

Bioengineered Mesenchymal Stem/Stromal Cells in Anti-Cancer Therapy: Current Trends and Future Prospects.

Gil-Chinchilla J, Zapata A, Moraleda J, Garcia-Bernal D Biomolecules. 2024; 14(7).

PMID: 39062449 PMC: 11275142. DOI: 10.3390/biom14070734.

References

Yin Z, Jiang K, Li R, Dong C, Wang L . Multipotent mesenchymal stromal cells play critical roles in hepatocellular carcinoma initiation, progression and therapy. Mol Cancer. 2018; 17(1):178. PMC: 6309092. DOI: 10.1186/s12943-018-0926-6. View

de Araujo Farias V, OValle F, Serrano-Saenz S, Anderson P, Andres E, Lopez-Penalver J . Exosomes derived from mesenchymal stem cells enhance radiotherapy-induced cell death in tumor and metastatic tumor foci. Mol Cancer. 2018; 17(1):122. PMC: 6094906. DOI: 10.1186/s12943-018-0867-0. View

Zhang N, Li L, Luo J, Tan J, Hu W, Li Z . Inhibiting microRNA-424 in bone marrow mesenchymal stem cells-derived exosomes suppresses tumor growth in colorectal cancer by upregulating TGFBR3. Arch Biochem Biophys. 2021; 709:108965. DOI: 10.1016/j.abb.2021.108965. View

Van Rooij E, Kauppinen S . Development of microRNA therapeutics is coming of age. EMBO Mol Med. 2014; 6(7):851-64. PMC: 4119351. DOI: 10.15252/emmm.201100899. View

Liang L, Zhao L, Wang Y, Wang Y . Treatment for Hepatocellular Carcinoma Is Enhanced When Norcantharidin Is Encapsulated in Exosomes Derived from Bone Marrow Mesenchymal Stem Cells. Mol Pharm. 2021; 18(3):1003-1013. DOI: 10.1021/acs.molpharmaceut.0c00976. View

Nail H, Chiu C, Leung C, Ahmed M, Wang H . Exosomal miRNA-mediated intercellular communications and immunomodulatory effects in tumor microenvironments. J Biomed Sci. 2023; 30(1):69. PMC: 10440907. DOI: 10.1186/s12929-023-00964-w. View

Jafari A, Babajani A, Abdollahpour-Alitappeh M, Ahmadi N, Rezaei-Tavirani M . Exosomes and cancer: from molecular mechanisms to clinical applications. Med Oncol. 2021; 38(4):45. DOI: 10.1007/s12032-021-01491-0. View

Taghehchian N, Alemohammad R, Farshchian M, Asoodeh A, Abbaszadegan M . Inhibitory role of LINC00332 in gastric cancer progression through regulating cell EMT and stemness. Life Sci. 2022; 305:120759. DOI: 10.1016/j.lfs.2022.120759. View

Chen H, Li J, Jiang F, Shi W, Chang G . MicroRNA-4461 derived from bone marrow mesenchymal stem cell exosomes inhibits tumorigenesis by downregulating COPB2 expression in colorectal cancer. Biosci Biotechnol Biochem. 2019; 84(2):338-346. DOI: 10.1080/09168451.2019.1677452. View

10.

Yang X, Shen Z, Tian M, Lin Y, Li L, Chai T . LncRNA C9orf139 can regulate the progression of esophageal squamous carcinoma by mediating the miR-661/HDAC11 axis. Transl Oncol. 2022; 24:101487. PMC: 9352544. DOI: 10.1016/j.tranon.2022.101487. View

11.

Xu Y, Shen L, Li F, Yang J, Wan X, OuYang M . microRNA-16-5p-containing exosomes derived from bone marrow-derived mesenchymal stem cells inhibit proliferation, migration, and invasion, while promoting apoptosis of colorectal cancer cells by downregulating ITGA2. J Cell Physiol. 2019; 234(11):21380-21394. DOI: 10.1002/jcp.28747. View

12.

Yu L, Gui S, Liu Y, Qiu X, Zhang G, Zhang X . Exosomes derived from microRNA-199a-overexpressing mesenchymal stem cells inhibit glioma progression by down-regulating AGAP2. Aging (Albany NY). 2019; 11(15):5300-5318. PMC: 6710058. DOI: 10.18632/aging.102092. View

13.

Zhang H, Wang J, Ren T, Huang Y, Liang X, Yu Y . Bone marrow mesenchymal stem cell-derived exosomal miR-206 inhibits osteosarcoma progression by targeting TRA2B. Cancer Lett. 2020; 490:54-65. DOI: 10.1016/j.canlet.2020.07.008. View

14.

Wu H, Mu X, Liu L, Wu H, Hu X, Chen L . Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung cancer cells via targeting LRRC1. Cell Death Dis. 2020; 11(9):801. PMC: 7519084. DOI: 10.1038/s41419-020-02962-4. View

15.

Sarugaser R, Lickorish D, Baksh D, Hosseini M, Davies J . Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells. 2005; 23(2):220-9. DOI: 10.1634/stemcells.2004-0166. View

16.

Bella F, Campo S . Long non-coding RNAs and their involvement in bipolar disorders. Gene. 2021; 796-797:145803. DOI: 10.1016/j.gene.2021.145803. View

17.

Haney M, Klyachko N, Zhao Y, Gupta R, Plotnikova E, He Z . Exosomes as drug delivery vehicles for Parkinson's disease therapy. J Control Release. 2015; 207:18-30. PMC: 4430381. DOI: 10.1016/j.jconrel.2015.03.033. View

18.

Hosseini Shamili F, Bayegi H, Salmasi Z, Sadri K, Mahmoudi M, Kalantari M . Exosomes derived from TRAIL-engineered mesenchymal stem cells with effective anti-tumor activity in a mouse melanoma model. Int J Pharm. 2018; 549(1-2):218-229. DOI: 10.1016/j.ijpharm.2018.07.067. View

19.

Zhang Z, Guo X, Guo X, Yu R, Qian M, Wang S . MicroRNA-29a-3p delivery via exosomes derived from engineered human mesenchymal stem cells exerts tumour suppressive effects by inhibiting migration and vasculogenic mimicry in glioma. Aging (Albany NY). 2021; 13(4):5055-5068. PMC: 7950307. DOI: 10.18632/aging.202424. View

20.

Seo B, Miura M, Gronthos S, Bartold P, Batouli S, Brahim J . Investigation of multipotent postnatal stem cells from human periodontal ligament. Lancet. 2004; 364(9429):149-55. DOI: 10.1016/S0140-6736(04)16627-0. View